Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus TREMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus TREMIN.
CHLORPROMAZINE HYDROCHLORIDE vs TREMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonizes dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histamine H1, muscarinic, and serotonin receptors.
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the basal ganglia, restoring the balance between dopaminergic and cholinergic activity, thereby reducing extrapyramidal symptoms.
25-100 mg orally or intramuscularly every 4-6 hours; maximum 2 g/day orally or 1 g/day intramuscularly.
1 mg orally 1-2 times daily, gradually increasing by 1 mg every 5-7 days up to 12 mg/day in divided doses. Maximum dose 12 mg/day.
None Documented
None Documented
Terminal elimination half-life 30 ± 14 hours (range 20–70 hours); clinical context: requires multiple daily dosing in acute agitation, but long-acting IM formulations (not chlorpromazine) available; half-life increases with age and hepatic impairment.
Terminal elimination half-life: 16 hours (range 12–20 hours) in adults, supporting twice-daily dosing; 35 hours in elderly patients
Primarily hepatic metabolism; renal excretion accounts for ~20% as unchanged drug and metabolites, with ~6% unchanged; biliary/fecal excretion ~80%, mainly as metabolites.
Renal: 40% unchanged; fecal: 60% as metabolites
Category C
Category C
Antipsychotic
Antipsychotic